Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

I. V. Subramanian; R. Ghebre; S. Ramakrishnan

doi:10.1038/sj.gt.3302352

Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

I. V. Subramanian, R. Ghebre, S. Ramakrishnan

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.

Original language	English (US)
Pages (from-to)	30-38
Number of pages	9
Journal	Gene therapy
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/sj.gt.3302352
State	Published - Jan 2005

Bibliographical note

Funding Information:
We thank Dr C Le and RL Bliss (Biostatistics Core, University of Minnesota Cancer Center) for statistical analysis. We also thank Dr Y Yokoyama for helpful suggestions. This work was supported in part by grants from the Minnesota Ovarian Cancer Alliance, Sparboe and Women’s Health Fund Endowment and DAM 17-99-1-9564 from the USARMY.

Keywords

Angiogenesis
Endostatin
Mouse model
Ovarian cancer
rAAV

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/sj.gt.3302352

OpenUrl availability

Full text

Cite this

@article{6c45870489c249ceb39e6e75614070b8,

title = "Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice",

abstract = "Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.",

keywords = "Angiogenesis, Endostatin, Mouse model, Ovarian cancer, rAAV",

author = "Subramanian, {I. V.} and R. Ghebre and S. Ramakrishnan",

note = "Funding Information: We thank Dr C Le and RL Bliss (Biostatistics Core, University of Minnesota Cancer Center) for statistical analysis. We also thank Dr Y Yokoyama for helpful suggestions. This work was supported in part by grants from the Minnesota Ovarian Cancer Alliance, Sparboe and Women{\textquoteright}s Health Fund Endowment and DAM 17-99-1-9564 from the USARMY.",

year = "2005",

month = jan,

doi = "10.1038/sj.gt.3302352",

language = "English (US)",

volume = "12",

pages = "30--38",

journal = "Gene therapy",

issn = "0969-7128",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

AU - Subramanian, I. V.

AU - Ghebre, R.

AU - Ramakrishnan, S.

N1 - Funding Information: We thank Dr C Le and RL Bliss (Biostatistics Core, University of Minnesota Cancer Center) for statistical analysis. We also thank Dr Y Yokoyama for helpful suggestions. This work was supported in part by grants from the Minnesota Ovarian Cancer Alliance, Sparboe and Women’s Health Fund Endowment and DAM 17-99-1-9564 from the USARMY.

PY - 2005/1

Y1 - 2005/1

N2 - Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.

AB - Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAV-P125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor- and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aendo construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth.

KW - Angiogenesis

KW - Endostatin

KW - Mouse model

KW - Ovarian cancer

KW - rAAV

UR - http://www.scopus.com/inward/record.url?scp=11844275275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844275275&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302352

DO - 10.1038/sj.gt.3302352

M3 - Article

C2 - 15550927

AN - SCOPUS:11844275275

SN - 0969-7128

VL - 12

SP - 30

EP - 38

JO - Gene therapy

JF - Gene therapy

IS - 1

ER -

Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this